Form D · Pharmaceuticals

Tolero Pharmaceuticals, Inc.

Lehi, UT · CIK 0001554907

Offering snapshot reported Dec 10, 2014 · SEC filing

Reported sold
$22.5M
Offering amount: $35.5M
Investors reported
48
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 4, 2014
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$11.2M$22.5MAug 18, 2014: $14,160,961.00Aug 18, 2014Nov 13, 2014: $21,861,077.00Nov 13, 2014Dec 10, 2014: $22,490,179.00Dec 10, 2014

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$21,861,077 → $22,490,179
  • Reported investors44 → 48

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 10, 2014Amendment$22,490,179$629,102vs Nov 13, 201448SEC filing
Nov 13, 2014Amendment$21,861,077$7,700,116vs Aug 18, 201444SEC filing
Aug 18, 2014Initial$14,160,961No comparison26SEC filing
Jul 27, 2012Initial$3,334,560No comparison9SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$1.49M
Form D file number
021-223152
$16,702,073 new money; $5,318,870.85 conversion of convertible promissory notes (principal and accrued interest); $469,236.07 warrants to purchase common stock

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
T.R. Winston & Company, LLC10571T.R. Winston & Company, LLC · CRD 10571

Source: Form D, filed Dec 10, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Dallin Anderson Director, Executive, Promoter
David Bearss Director, Executive
David Bearss, Ph.D. Director, Executive, Promoter

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
2975 Executive Parkway Suite 320
Lehi, UT, 84043